Этот веб-сайт использует файлы cookies. Соглашаясь использовать файлы cookies, вы делаете пользование веб-сайтом более удобным. Прочитать подробнее.
Germany: BioNTech and Pfizer announce '90 percent effective' COVID vaccine01:34

Germany: BioNTech and Pfizer announce '90 percent effective' COVID vaccine

Германия, Mainz
9 November, 2020 в 17:52 GMT +00:00 · Опубликовано

German company BioNTech and its American associate Pfizer announced on Monday that their experimental coronavirus vaccine was more than "90 percent effective" against COVID-19 infections.

Footage show the BioNTech offices in Mainz on Monday.

"I am happy to share with you that Pfizer and our collaborator, BioNTech, announced positive efficacy results from our Phase three, late-stage study of our potential COVID-19 vaccine. The vaccine candidate was found to be more than 90 percent effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-Two infection in the first interim efficacy analysis," explained Pfizer chairman and CEO Albert Bourla in a statement.

"This means we are one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic," Bourla added.

The two pharmaceutical companies said they are planning to produce up to 50 million vaccine doses in 2020 and up to one point three billion doses in 2021, pending extensive research and approval by the US Food and Drug Administration (FDA).

Germany: BioNTech and Pfizer announce '90 percent effective' COVID vaccine01:34
Нет аккаунта? Зарегистрируйтесь!
В трендеView all videos
Самые скачиваемые видео за последние 24 часа
Показать еще
Описание

German company BioNTech and its American associate Pfizer announced on Monday that their experimental coronavirus vaccine was more than "90 percent effective" against COVID-19 infections.

Footage show the BioNTech offices in Mainz on Monday.

"I am happy to share with you that Pfizer and our collaborator, BioNTech, announced positive efficacy results from our Phase three, late-stage study of our potential COVID-19 vaccine. The vaccine candidate was found to be more than 90 percent effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-Two infection in the first interim efficacy analysis," explained Pfizer chairman and CEO Albert Bourla in a statement.

"This means we are one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic," Bourla added.

The two pharmaceutical companies said they are planning to produce up to 50 million vaccine doses in 2020 and up to one point three billion doses in 2021, pending extensive research and approval by the US Food and Drug Administration (FDA).